Emmanuel Odi
Internal Medicine · Birmingham, ALNPI 1215976451
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 489 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,349 and has fallen 98.7% since, to $30 in 2025. Among internal medicine clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 489 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$792
- AstraZeneca$705
- AbbVie$701
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$529
- Johnson & Johnson$398
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,63599%
- Education$931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 90 | $1,249 |
| Lilly USA, LLC | 49 | $792 |
| AstraZeneca | 44 | $705 |
| AbbVie(2 entities) | 62 | $701 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $529 |
| Johnson & Johnson | 20 | $398 |
| Amgen(2 entities) | 22 | $381 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $326 |
| Merck | 19 | $320 |
| GSK | 18 | $283 |
| Pfizer | 16 | $259 |
| Biohaven Pharmaceuticals, Inc. | 11 | $227 |
| Vivus LLC | 12 | $201 |
| Assertio Therapeutics, Inc. | 13 | $195 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $150 |
| Astellas Pharma US Inc | 6 | $148 |
| Boehringer Ingelheim | 7 | $118 |
| Amarin Pharma, Inc. | 7 | $116 |
| Eisai Inc. | 7 | $104 |
| Zyla Life Sciences, Inc. | 4 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Arbor Pharmaceuticals, Inc. | 3 | $49 |
| Mannkind Corporation | 3 | $48 |
| Dexcom, Inc. | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Calliditas Therapeutics US Inc. | 1 | $25 |
| Medtronic | 1 | $22 |
| Bayer | 1 | $21 |
| Novartis | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$7,728 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Birmingham
- Ryan WeldonBirmingham$458K
- Robert LewisBirmingham$187K
- Thomas HuddleBirmingham$76K
- Jose VargasBirmingham$49K
- Donna FicoBirmingham$46K
- James SullivanBirmingham$39K
- Ross SchumacherBirmingham$26K
- Larry AlfordBirmingham$25K
- David WynneBirmingham$22K
- James CrenshawBirmingham$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.